Cantor Fitzgerald Reiterates Positive View on Amarin (AMRN) Following Final ICER Report

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $35.00 price target on Amarin Corporation (NASDAQ: AMRN) after the company announced that an independent organization that evaluates pricing of prescription drugs, ICER, has issued its final report assessing the cost-effectiveness of Vascepa.

The final assessment confirms the cost-effectiveness of Vascepa across all the non-profit organization’s analyses, including its most stringent criteria, the analyst notes.

"Despite the stringent criteria of the analysis, the report concludes that Vascepa easily meets "commonly cited thresholds for cost-effectiveness and therefore represents a high long-term value for money."", the analyst highlights. "This report underscores the findings of the landmark REDUCE-IT trial and strengthens our belief that the peak sales potential of Vascepa is underappreciated."

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $16.05 yesterday.

You May Also Be Interested In

• BMO Capital Starts Cadillac Mines Corp (CADY:CN) at Outperform
• Bernstein SocGen Group Upgrades Whitbread PLC. (WTB:LN) (WTBCF) to Market Perform
• JPMorgan Upgrades America Movil (AMX) to Overweight